Science & Health

Latest Stories

UK Mental Health Technology Platform Secures £4 Million AI Investment

Written by: Archie Williamson | Posted: 06-06-2024

UK Mental Health Technology Platform Secures £4 Million AI Investment

This is an AI-generated image created with Midjourney by Molly-Anna MaQuirl

Is Psyomics' £4m AI Breakthrough a Game Changer for Mental Health?

One of the top-notch UK-based mental health tech companies, Psyomics, is poised to transform mental health diagnosis with major AI breakthroughs thanks to the securement of £4m in funding. Parkwalk Advisors further supports the funding with up to £3.5m. However, questions arise about Psyomics's mission and how it is spending the funding. 

Funds Involvement: How is it Impacting Youth Mental Health? 

The new funding will support the enhancement of Censeo's capabilities for young people and children. Censeo is an AI-driven medical device that involves a range of assessments and trials on neurodiversity screening. This innovative initiative is vital as most mental health disorders (around 75%) start to show before the age of 18. Parkwalk Advisors believed in the global potential of Psyomics' innovative technology not only in the UK but also worldwide. It stands as an outstanding model of the UK universities' contribution to healthcare. 

Do Psyomics' AI breakthroughs differ from traditional procedures? 

Psyomics' AI-driven technology is ostensibly advanced compared to traditional procedures for identifying mental health conditions. It uses progressive AI algorithms, such as natural language techniques and deep learning, to make quick diagnoses and detect vast patterns by analysing data, making a cutting-edge impact. 

According to a case study by the British Psychological Society, Psyomics' AI-based assessments are involved in accurately diagnosing mental health conditions with improved cognitive ability tests and treatment outcomes. 

Psyomics' AI-driven Assessments: Addressing the Mental Health Challenge 

  • Around 75% of young people facing mental health issues (around 1.4 million people) are waiting for treatment due to the extended delays in the UK.
  • In this critical situation, Psyomics proposes revolutionary diagnoses, trials and treatment options that have been developed in partnership with clinical experts and a skilled neurotechnology team from the University of Cambridge.
  • Censeo, with its wide range of biopsychological profiles, supports fast algorithms to execute personalised comprehensive analysis.
  • Psyomics offers a friendly interface and precise reports for healthcare teams and patients. Early patients have praised AI-driven devices as accurate, quicker, and user-friendly.

Is this investment worthwhile to focus on and scaling up the growth of its development? 

The funding plays a dual role in enhancing AI ability and scaling up development, which ensures that Psyomics can make a potential impact and be accessible to a wide range of audiences. 81% of clinicians report that the quality of care and speed are enhanced by 50% in patient trials and diagnoses. This efficient result allows more professionals to stay focused on treatment rather than spending time on patient trial and care of diagnosis. 

CEO of Psyomics, Dr Melinda Rees, pays attention to the significant role of the new developments:

"As Censeo cuts down the long waiting lists of patients and streamlines the diagnosis procedure, it's a great time to free up the clinicians and professionals to focus on treatment goals. With the help of funding, young people and children can develop a better service via our platform." 

Lastly, is it a transformative journey in reshaping the mental health diagnosis? 

Psyomics will continue its international journey on AI's assessment abilities and explore innovative approaches to mental health conditions while maintaining a competitive edge in technology. 

The initial targets on its list are North America and Europe. However, over the next five years, Psyomics' mission is to reach a global audience, reduce the healthcare professionals' administrative burden and improve patient care by providing easy access to an accurate, personalised diagnosis system.

 

 

*Disclaimer: When published, this article unintentionally contained the following incorrect statement: "Around 75% of young people are facing mental health issues". We have now rectified this with the correct information above. Part of our mission is to combat misinformation, and so we apologise for any confusion caused. 

Explore More News

UK Mental Health Technology Platform Secures £4 Million AI Investment

Written by: Archie Williamson | Posted: 06-06-2024

UK Mental Health Technology Platform Secures £4 Million AI Investment

This is an AI-generated image created with Midjourney by Molly-Anna MaQuirl

Is Psyomics' £4m AI Breakthrough a Game Changer for Mental Health?

One of the top-notch UK-based mental health tech companies, Psyomics, is poised to transform mental health diagnosis with major AI breakthroughs thanks to the securement of £4m in funding. Parkwalk Advisors further supports the funding with up to £3.5m. However, questions arise about Psyomics's mission and how it is spending the funding. 

Funds Involvement: How is it Impacting Youth Mental Health? 

The new funding will support the enhancement of Censeo's capabilities for young people and children. Censeo is an AI-driven medical device that involves a range of assessments and trials on neurodiversity screening. This innovative initiative is vital as most mental health disorders (around 75%) start to show before the age of 18. Parkwalk Advisors believed in the global potential of Psyomics' innovative technology not only in the UK but also worldwide. It stands as an outstanding model of the UK universities' contribution to healthcare. 

Do Psyomics' AI breakthroughs differ from traditional procedures? 

Psyomics' AI-driven technology is ostensibly advanced compared to traditional procedures for identifying mental health conditions. It uses progressive AI algorithms, such as natural language techniques and deep learning, to make quick diagnoses and detect vast patterns by analysing data, making a cutting-edge impact. 

According to a case study by the British Psychological Society, Psyomics' AI-based assessments are involved in accurately diagnosing mental health conditions with improved cognitive ability tests and treatment outcomes. 

Psyomics' AI-driven Assessments: Addressing the Mental Health Challenge 

  • Around 75% of young people facing mental health issues (around 1.4 million people) are waiting for treatment due to the extended delays in the UK.
  • In this critical situation, Psyomics proposes revolutionary diagnoses, trials and treatment options that have been developed in partnership with clinical experts and a skilled neurotechnology team from the University of Cambridge.
  • Censeo, with its wide range of biopsychological profiles, supports fast algorithms to execute personalised comprehensive analysis.
  • Psyomics offers a friendly interface and precise reports for healthcare teams and patients. Early patients have praised AI-driven devices as accurate, quicker, and user-friendly.

Is this investment worthwhile to focus on and scaling up the growth of its development? 

The funding plays a dual role in enhancing AI ability and scaling up development, which ensures that Psyomics can make a potential impact and be accessible to a wide range of audiences. 81% of clinicians report that the quality of care and speed are enhanced by 50% in patient trials and diagnoses. This efficient result allows more professionals to stay focused on treatment rather than spending time on patient trial and care of diagnosis. 

CEO of Psyomics, Dr Melinda Rees, pays attention to the significant role of the new developments:

"As Censeo cuts down the long waiting lists of patients and streamlines the diagnosis procedure, it's a great time to free up the clinicians and professionals to focus on treatment goals. With the help of funding, young people and children can develop a better service via our platform." 

Lastly, is it a transformative journey in reshaping the mental health diagnosis? 

Psyomics will continue its international journey on AI's assessment abilities and explore innovative approaches to mental health conditions while maintaining a competitive edge in technology. 

The initial targets on its list are North America and Europe. However, over the next five years, Psyomics' mission is to reach a global audience, reduce the healthcare professionals' administrative burden and improve patient care by providing easy access to an accurate, personalised diagnosis system.

 

 

*Disclaimer: When published, this article unintentionally contained the following incorrect statement: "Around 75% of young people are facing mental health issues". We have now rectified this with the correct information above. Part of our mission is to combat misinformation, and so we apologise for any confusion caused.